Hiển thị các bài đăng có nhãn study. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn study. Hiển thị tất cả bài đăng

Thứ Sáu, 10 tháng 2, 2012

Stopping Bone Drug Cuts Risk of Second Thigh Fracture: Study

THURSDAY, Feb. 9 (HealthDay News) -- People who suffer a rare type of fracture of the thigh bone while taking bone-building drugs known as bisphosphonates can cut the risk of a second fracture by discontinuing the medication, a new study says.

Bisphosphonates such as Fosamax, Boniva and Actonel are often prescribed for postmenopausal women or people taking steroid medications to prevent or slow the bone-weakening disease osteoporosis. But the drugs have been linked to a small risk of unusual fractures of the femur. One out of 1,000 taking the drugs for six years will suffer such a fracture, the researchers said.

For the study, the researchers examined femur fracture records for patients older than 45 from a large California insurer. Over two years, they found 126 patients reportedly taking bisphosphonates suffered an atypical femur fracture.

Of those patients, 41.2 percent who continued taking the drugs suffered a second femur fracture in the other thigh three or more years later. In contrast, 19.3 percent of those who stopped taking the medication had a similar break. Overall, the study revealed, subsequent atypical femur fractures dropped by 53 percent -- more than half -- when patients stopped taking bisphosphonates after the first break.

"The risk of a contralateral atypical femur fracture [on the opposite side] increases over time if the bisphosphonates are continued," said lead investigator Dr. Richard Dell, a researcher in the department of orthopedics at Kaiser Permanente.

"Based on these observations, we recommend discontinuing bisphosphonate use as soon as possible after the initial atypical femur fracture has occurred," Dell said in a news release from the American Academy of Orthopaedic Surgeons.

The study authors speculated that bisphosphonates may disrupt the bone remodeling process, whereby bones replace old tissue with healthy new bone tissue. The result might be brittle bones that break more easily. In these cases, the femur is at particular risk.

Patients on bisphosphonates who suffer this rare femur fracture also need ongoing evaluation since they remain at greater risk for another break, Dell added. They probably should use another osteoporosis medication, he said.

The findings were slated for presentation Wednesday at the annual meeting of the American Academy of Orthopaedic Surgeons in San Francisco.

Research presented at medical meetings should be considered preliminary until published in a peer-reviewed medical journal.

More information

The U.S. National Institutes of Health provides more information on osteoporosis.


View the original article here

Study on mice shows fasting weakens cancer

Early research on mice with cancer shows that fasting may weaken tumors and help chemotherapy work better, scientists said on Wednesday.

While it remains unknown if the same approach could work in humans, or if it would even be safe, researchers said the findings suggest a promising new route of study for improving response to cancer treatment.

In the mice experiments, "the combination of fasting cycles plus chemotherapy was either more or much more effective than chemo alone," said senior author Valter Longo, professor of gerontology and biological sciences at the University of Southern California (USC).

Longo and colleagues previously published findings in 2008 that showed how fasting protected normal cells against chemotherapy in a study that focused on one type of cancer and a single chemo drug.

The latest study expands on that research to show that fasting makes cancer cells more vulnerable, and spanned several different types of cancer in mice.

Types of cancers studied included breast cancer, melanoma, glioma and human neuroblastoma.

All cancers studied showed that fasting combined with chemotherapy improved survival, slowed the growth of tumors and/or limited their spread.

The study appears in the journal Science Translational Medicine.

"We don't know whether in humans it's effective," Longo said, adding that for now fasting should be "off-limits" to cancer patients, although they should feel they can ask their doctors about the possibility.

In 2010, a small study of 10 human cancer patients who tried fasting cycles with their drug treatment showed that they perceived fewer side effects from chemo, according to self-reported data. The study was published in the journal Aging.

The results of a phase 1 trial assessing the safety of fasting two days before and one day after chemotherapy in patients with breast, urinary tract and ovarian cancer, conducted at the USC, have been submitted for presentation at the annual meeting of the American Society of Cancer Oncologists later this year.

"A way to beat cancer cells may not be to try to find drugs that kill them specifically but to confuse them by generating extreme environments, such as fasting that only normal cells can quickly respond to," Longo said.

ksh/rl


View the original article here

Thứ Tư, 8 tháng 2, 2012

Fasting Plus Chemo May Help in Cancer Fight: Study

WEDNESDAY, Feb. 8 (HealthDay News) -- Fasting, especially when combined with chemotherapy, appears to slow the growth of cancerous tumors in mice, new research suggests.

Experts note that the results of animal studies often don't hold up when tried in humans.

However, researchers have started testing whether fasting can help human patients with breast, ovarian and urinary tract cancer.

In the mouse study, published in the current issue of Science Translational Medicine, researchers found that fasting slowed the growth of growth of breast cancer, melanoma, glioma and human neuroblastoma in mice.

In some cases, fasting was as effective as chemotherapy, according to the study.

"The combination of fasting cycles plus chemotherapy was either more or much more effective than chemo alone," senior study author Valter Longo, a professor of gerontology and biological sciences at the University of Southern California, said in a university news release.

Researchers said that normal cells deprived of nutrients during fasting enter a dormant state, whereas when studied in the lab, a type of cancer cell attempted to keep growing and dividing.

That, in turn, led to a "cascade of events" that damaged the cancer cells' DNA and led to cell death.

"A way to beat cancer cells may not be to try to find drugs that kill them specifically but to confuse them by generating extreme environments, such as fasting, that only normal cells can quickly respond to," Longo concluded.

The study authors noted that results from the initial phase of a clinical trial, which involved patients with breast, urinary tract and ovarian cancer conducted at the USC Norris Comprehensive Cancer Center, have been submitted for presentation at the annual meeting of the American Society of Cancer Oncologists. This trial tested the safety of short-term fasts two days before and one day after chemotherapy.

"We don't know whether in humans it's effective," Longo said. "It should be off limits to patients, but a patient should be able to go to their oncologist and say, 'What about fasting with chemotherapy or without' if chemotherapy was not recommended or considered?"

The researchers warned that fasting may not be safe for all cancer patients, particularly those who have already lost a significant amount of weight or have other conditions, such as diabetes. They added that fasting can cause headaches and a drop in blood pressure. The study also pointed out that cancer-free survival resulting from fasting may not extend to large tumors.

According to the American Cancer Society, "available scientific evidence does not support claims that fasting is effective for preventing or treating cancer. Even a short-term fast can have negative health effects, while fasting for a longer time could cause serious health problems."

More information

The American Cancer Society provides more information on fasting and cancer.


View the original article here

Study on mice shows fasting weakens cancer

Early research on mice with cancer shows that fasting may weaken tumors and help chemotherapy work better, scientists said on Wednesday.

While it remains unknown if the same approach could work in humans, or if it would even be safe, researchers said the findings suggest a promising new route of study for improving response to cancer treatment.

In the mice experiments, "the combination of fasting cycles plus chemotherapy was either more or much more effective than chemo alone," said senior author Valter Longo, professor of gerontology and biological sciences at the University of Southern California (USC).

Longo and colleagues previously published findings in 2008 that showed how fasting protected normal cells against chemotherapy in a study that focused on one type of cancer and a single chemo drug.

The latest study expands on that research to show that fasting makes cancer cells more vulnerable, and spanned several different types of cancer in mice.

Types of cancers studied included breast cancer, melanoma, glioma and human neuroblastoma.

All cancers studied showed that fasting combined with chemotherapy improved survival, slowed the growth of tumors and/or limited their spread.

The study appears in the journal Science Translational Medicine.

"We don't know whether in humans it's effective," Longo said, adding that for now fasting should be "off-limits" to cancer patients, although they should feel they can ask their doctors about the possibility.

In 2010, a small study of 10 human cancer patients who tried fasting cycles with their drug treatment showed that they perceived fewer side effects from chemo, according to self-reported data. The study was published in the journal Aging.

The results of a phase 1 trial assessing the safety of fasting two days before and one day after chemotherapy in patients with breast, urinary tract and ovarian cancer, conducted at the USC, have been submitted for presentation at the annual meeting of the American Society of Cancer Oncologists later this year.

"A way to beat cancer cells may not be to try to find drugs that kill them specifically but to confuse them by generating extreme environments, such as fasting that only normal cells can quickly respond to," Longo said.


View the original article here

Breast Cancer Drug May Weaken Bones, Study Finds

TUESDAY, Feb. 7 (HealthDay News) -- A drug used to prevent breast cancer in women at high risk for the disease appears to cause bone loss in some postmenopausal women, a new study finds.

The drug, Aromasin (exemestane), has been shown to reduce the odds of breast cancer by 65 percent, but it also worsens bone density by about three times in older women who are taking it, Canadian researchers report.

"The drug did affect bone density at the hip and spine," said lead researcher Dr. Angela Cheung, a senior scientist at the University Health Network in Toronto. "It does not affect everyone; about 65 percent of women have some bone loss."

The fear of bone loss is not a reason not to take the drug, Cheung said. "You really need to pay attention to your bone health when you take this medication, especially for preventing breast cancer."

However, for women who are at high risk for fractures, other drugs should be considered, she added.

Women taking this drug should also be taking calcium and vitamin D supplements, and having their bone density monitored, Cheung said.

An older drug, tamoxifen, actually builds bone, but it is not as effective at preventing breast cancer, she said. "But, for someone with healthy bones it is worthwhile taking the medication."

Exemestane is an aromatase inhibitor and works by suppressing the female hormone estrogen. These drugs are standard treatment for postmenopausal women with early stage hormone-receptor-positive breast cancer.

It had been speculated that exemestane, a third-generation aromatase inhibitor, might result in less bone loss than other similar drugs and might even stimulate bone formation.

For the new study, Cheung's team looked at bone loss among the more than 4,500 women who took part in a trial that compared exemestane with a placebo.

Among women taking the drug, the risk of developing breast cancer was lowered 65 percent, compared with women taking a placebo.

Among the 351 women in whom bone loss was studied, the researchers found that after two years there was an 8 percent loss of cortical bone in women taking exemestane, compared with 1 percent in the placebo group.

Cortical bone is the outer shell of bone that provides most of the bone support, and its loss accounts for about 80 percent of fractures in older people, the researchers noted.

The findings were published in the Feb. 6 online edition of The Lancet Oncology.

Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, was somewhat cautious about the new research. She said that "the study needs longer follow-up to see if there is an increased risk of fracture."

"This study doesn't mean that we should stop using these drugs," she said. "We certainly rely on aromatase inhibitors more than tamoxifen in postmenopausal women, because the survival benefit has been proven."

The benefit of the drug outweighs that risk for most women, she said. However, if there is a family history of osteoporosis it may not be the best choice, Bernik said.

More information

For more on breast cancer, visit the American Cancer Society.


View the original article here

Avoid Window Seats to Cut Risk for In-Flight Blood Clots: Study

TUESDAY, Feb. 7 (HealthDay News) -- Potentially dangerous blood clots in the legs known as deep venous thromboses (DVTs) got the nickname "economy class syndrome" from widely publicized incidents involving passengers on long-haul flights.

However, new guidelines from a leading physicians' group suggest the class you sit in on a plane may not raise your DVT risk, but your proximity to the aisle might.

Sitting in a window seat is a risk factor for DVT, the American College of Chest Physicians (ACCP) warn in their new advisory, regardless of whether it's in economy or first class.

"DVT risk has nothing to do with economy class," said Dr. Gordon H. Guyatt, chair of the ACCP panel that drafted the new guidelines. "Really, the evidence is that actually where you sit isn't really an issue. It's how much you move around. And if you're in a window seat you are probably more willing to sit for long periods of time being uncomfortable because you are reluctant to make anybody else move to let you out."

The new recommendations are published in the February issue of CHEST.

DVTs are blood clots that typically occur in the legs. They can become especially dangerous if they travel through the bloodstream to the lungs, where they can form potentially lethal pulmonary embolisms.

The current guidelines, which are endorsed by a wide range of American medical associations, are the ninth in a series of ACCP updates on the issue. They were drafted after the panel extensively reviewed findings from relevant studies published since the last update in 2008.

Long-haul immobility does boost DVT risk, the experts noted. But as the ACCP panel sifted through the evidence, they found no basis for the notion of "economy class syndrome." Rather, folks in a window seat might be more hesitant to get up and move around -- and that might raise their odds for a DVT.

Still, "the first thing to say is that if you are a healthy person you should not really worry about DVT because your risk -- even on a long-term flight -- is considerably less than one in a thousand," said Guyatt, who is also professor in the department of clinical epidemiology and biostatistics at McMaster University in Hamilton, Ontario, Canada. "So these guidelines are for those who have more than a normal risk. For those who have had a clot before, or an abnormality of their coagulation system, or disability that affects mobility. Or if you are obese or have active cancer."

In addition to those risk factors, the ACCP says that air passengers who are elderly, pregnant, take supplementary estrogen (including oral contraceptives) or recently underwent surgery and/or trauma also face a higher-than-normal risk for DVT.

Apart from seating considerations, the guidelines also suggest that people on flights lasting six or more hours move about frequently and stretch their calf muscles.

Higher-risk individuals should also wear graduated compression stockings that stretch below the knee. Guyatt said it "would be crazy" for passengers at normal risk to wear such stockings, and the ACCP guidelines specifically argue against their use by healthy passengers.

The guidelines also generally discourage the taking of aspirin and/or anticoagulant medications for the specific intent of lowering DVT risk. That said, those at very high risk are encouraged to consult their doctors in order to weigh the pros and cons of such drugs.

For his part, Dr. Christopher Cannon, a cardiologist at Brigham and Women's Hospital in Boston, said the new DVT guidelines "make obvious good sense."

"Getting up once every hour or two during a long flight and walking up and down the aisle is what you want to do," he noted. "It's not about class and the slight extra room you'll get in business. It's about sitting by the window and looking over at the guy sleeping next to you and thinking you'll wait rather than get up. That's the issue."

"I would also add that all of this would also apply to people taking long car trips," Cannon said. "I've had tons of people driving home on long car rides who have had problems with DVT. Hence the emphasis on mobility. It's all about making sure you get up or get out and move."

More information

Find out more about DVT risk at the U.S. National Library of Medicine.


View the original article here

Thứ Ba, 7 tháng 2, 2012

Green tea drinkers show less disability with age: study

NEW YORK (Reuters Health) - Elderly adults who regularly drink green tea may stay more agile and independent than their peers over time, a large study of Japanese adults suggests.

Green tea contains certain antioxidant chemicals -- particularly a compound known as EGCG -- that may help ward off the body-cell damage that can lead to disease. And researchers have been studying green tea's effects on everything from cholesterol to the risk of certain cancers -- with mixed results so far.

For the new study, Japanese researchers looked at a different question: Do green-tea drinkers have any lower risk of frailty and disability as they grow old?

Following nearly 14,000 adults age 65 and older, they found that people who drank the most green tea were the least likely to develop "functional disability" over the next three years.

Functional disability refers to problems with daily activities like going to the store or doing housework, or difficulty with more-basic needs like dressing and bathing.

In this study, almost 13 percent of adults who drank less than a cup of green tea per day became functionally disabled. That compared with just over 7 percent of people who drank at least five cups per day.

That alone does not prove that green tea keeps you spry into your golden years.

But the study, reported in the American Journal of Clinical Nutrition, did account for a range of factors that could explain the connection.

Green-tea lovers generally had healthier diets -- more fish, vegetables and fruit -- as well as more education, lower smoking rates, fewer heart attacks and strokes and greater mental sharpness.

They also tended to be more socially active and have more friends and family to rely on. (Studies have found that older adults with more "social support" are less likely to become disabled.)

But even with those factors considered, green tea itself was tied to a lower disability risk, according to the researchers, led by Yasutake Tomata of Tohoku University Graduate School of Medicine.

People who drank at least five cups a day were one-third less likely to develop disabilities than those who had less than a cup a day. And people who averaged three or four cups a day had a 25 percent lower risk.

All of that hints at a real effect of green tea. But ultimately, Tomata's team writes, definitive proof can come only from clinical trials testing the effects of green tea, or green tea extracts, on disability risk.

If green tea does offer a buffer against disability, it's not clear how.

But one recent study found that green tea extracts seemed to boost leg muscle strength in older women, notes Tomata's team, who could not be reached for comment.

In general, green tea is considered safe in moderate amounts. But the tea and its extracts do contain caffeine, which some people may need to avoid.

Green tea also contains small amounts of vitamin K, which means it could interfere with drugs that prevent blood-clotting, like warfarin. Since many elderly people are on multiple medications, it's wise for them to talk with their doctors before using green tea as a health tonic.

SOURCE: http://bit.ly/wXuZbl American Journal of Clinical Nutrition, online January 25, 2012.


View the original article here

Malaria kills twice as many as thought: study

LONDON (Reuters) - Malaria kills more than 1.2 million people worldwide a year, nearly twice as many as previously thought, according to new research published on Friday that questions years of assumptions about the mosquito-borne disease.

Past studies had overlooked hundreds of thousands of deaths because they had wrongly assumed malaria overwhelmingly killed babies and focused their findings on under-fives, said the study by the Institute for Health Metrics and Evaluation (IHME) in the United States.

The new study, published in The Lancet medical journal, found 42 percent of deaths were actually among older children and adults.

The higher number of victims showed the need to increase funding to fight malaria, even as governments came under pressure to cut their aid budgets amid the global economic crisis, said the researchers.

"You learn in medical school that people exposed to malaria as children develop immunity and rarely die from malaria as adults," said Christopher Murray, who led the study as IHME Director. "What we've found in hospital records, death records, surveys and other sources shows that just is not the case."

In their work, which used new data and computer modelling to build a historical database for malaria between 1980 and 2010, they found that more than 78,000 children aged five to 14, and more than 445,000 people aged 15 and older died from malaria in 2010. This means more than four in 10 of all malaria deaths were in people aged fives years and older.

Overall, malaria deaths worldwide rose from 995,000 in 1980 to a peak of 1.8 million in 2004, before falling again to 1.2 million in 2010, the study found.

The World Health Organisation's (WHO) latest global report said the estimated number of malaria deaths fell to 655,000 in 2010, almost half the number in the IHME study.

The WHO, a United Nations agency, said on Friday it stood by its figures and said that much of the data used in the Lancet study had been based on verbal testimony by relatives of how people had died, not on laboratory diagnosis of samples.

"So we would say that again the great majority of deaths would be in children under five and we stand by our estimates," WHO spokesman Gregory Hartl told a news briefing in Geneva.

Both studies showed a downward trend in deaths in recent years, thanks largely to the use of anti-malaria drugs and insecticide-treated bed nets.

The new findings are part of an ongoing series generated by the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Global trends in child deaths, maternal deaths, breast cancer, and cervical cancer were released last year

and more will be released in coming months.

Malaria is endemic in more than 100 countries worldwide but can be prevented by the use of bed nets and indoor spraying to keep the mosquitoes that carry the disease at bay.

Effective malaria drugs known as artemisinin-based combination therapies, or ACTs, can cure the infection but access to these medicines is often hampered in poor countries, where funding is limited and health services are patchy.

The IHME researchers said much of the decline in deaths was down to efforts by the Global Fund to Fight AIDS, Malaria and Tuberculosis, which was launched in 2001, and other anti-malaria organisations such as the WHO's Roll Back Malaria campaign.

"We have seen a huge increase in both funding and in policy attention given to malaria over the past decade, and it's having a real impact," said Alan Lopez of the University of Queensland and one of the study's co-authors.

"Reliably demonstrating just how big an impact is important to drive further investments... This makes it even more critical for us to generate accurate estimates for all deaths."

The researchers also warned, as the WHO did in its December 2010 malaria report, that recent gains in the fight against the disease malaria could be reversed if global economic troubles stifle funding efforts.

It said an announcement by the Global Fund in November that it would cancel its next round of funding "casts a cloud over the future of malaria programs".

"If the Global Fund is weakened, the world could lose 40 percent of all the funding dedicated to fighting malaria," said Stephen Lim, also at IHME and a co-author on the study.


View the original article here

Malaria kills twice as many as thought: study

LONDON (Reuters) - Malaria kills more than 1.2 million people worldwide a year, nearly twice as many as previously thought, according to new research published on Friday that questions years of assumptions about the mosquito-borne disease.

Past studies had overlooked hundreds of thousands of deaths because they had wrongly assumed malaria overwhelmingly killed babies and focused their findings on under-fives, said the study by the Institute for Health Metrics and Evaluation (IHME) in the United States.

The new study, published in The Lancet medical journal, found 42 percent of deaths were actually among older children and adults.

The higher number of victims showed the need to increase funding to fight malaria, even as governments came under pressure to cut their aid budgets amid the global economic crisis, said the researchers.

"You learn in medical school that people exposed to malaria as children develop immunity and rarely die from malaria as adults," said Christopher Murray, who led the study as IHME Director. "What we've found in hospital records, death records, surveys and other sources shows that just is not the case."

In their work, which used new data and computer modelling to build a historical database for malaria between 1980 and 2010, they found that more than 78,000 children aged five to 14, and more than 445,000 people aged 15 and older died from malaria in 2010. This means more than four in 10 of all malaria deaths were in people aged fives years and older.

Overall, malaria deaths worldwide rose from 995,000 in 1980 to a peak of 1.8 million in 2004, before falling again to 1.2 million in 2010, the study found.

The World Health Organisation's (WHO) latest global report said the estimated number of malaria deaths fell to 655,000 in 2010, almost half the number in the IHME study.

The WHO, a United Nations agency, said on Friday it stood by its figures and said that much of the data used in the Lancet study had been based on verbal testimony by relatives of how people had died, not on laboratory diagnosis of samples.

"So we would say that again the great majority of deaths would be in children under five and we stand by our estimates," WHO spokesman Gregory Hartl told a news briefing in Geneva.

Both studies showed a downward trend in deaths in recent years, thanks largely to the use of anti-malaria drugs and insecticide-treated bed nets.

The new findings are part of an ongoing series generated by the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Global trends in child deaths, maternal deaths, breast cancer, and cervical cancer were released last year

and more will be released in coming months.

Malaria is endemic in more than 100 countries worldwide but can be prevented by the use of bed nets and indoor spraying to keep the mosquitoes that carry the disease at bay.

Effective malaria drugs known as artemisinin-based combination therapies, or ACTs, can cure the infection but access to these medicines is often hampered in poor countries, where funding is limited and health services are patchy.

The IHME researchers said much of the decline in deaths was down to efforts by the Global Fund to Fight AIDS, Malaria and Tuberculosis, which was launched in 2001, and other anti-malaria organisations such as the WHO's Roll Back Malaria campaign.

"We have seen a huge increase in both funding and in policy attention given to malaria over the past decade, and it's having a real impact," said Alan Lopez of the University of Queensland and one of the study's co-authors.

"Reliably demonstrating just how big an impact is important to drive further investments... This makes it even more critical for us to generate accurate estimates for all deaths."

The researchers also warned, as the WHO did in its December 2010 malaria report, that recent gains in the fight against the disease malaria could be reversed if global economic troubles stifle funding efforts.

It said an announcement by the Global Fund in November that it would cancel its next round of funding "casts a cloud over the future of malaria programs".

"If the Global Fund is weakened, the world could lose 40 percent of all the funding dedicated to fighting malaria," said Stephen Lim, also at IHME and a co-author on the study.


View the original article here

Anxiety therapy doesn't work as well in elderly: study

NEW YORK (Reuters Health) - A form of talk therapy called cognitive behavioral therapy appears to help older adults battle anxiety disorders slightly better than other approaches, but not as well as in younger adults, according to a new study.

"Cognitive behavioral therapy is the mainstay for treating anxiety disorders in younger adults. Its lower effect in older adults in this study is concerning," said Dr. Eric Lenze, a professor at Washington University School of Medicine, who was not involved in this study.

Anxiety disorders, which include panic disorder, phobias, post-traumatic stress and generalized anxiety disorder, are common in adults over age 55.

The authors write in the Journal of the American Geriatrics Society that three to 14 out of every 100 older adults has an anxiety disorder.

While earlier studies have shown that cognitive behavioral therapy works well for younger and middle-aged adults, there has not been as much research into the treatment for seniors.

"The prevailing assumption tends to be that what works with working-age people will work with older people, but this might not actually be the case," said Rebecca Gould, the lead author of the study and a researcher at King's College London.

Gould's team gathered up the results from 12 previous studies on people over age 55 with an anxiety disorder.

Half of the studies compared cognitive behavioral therapy to other treatments, such as medications or group discussions, while the other half compared the therapy to no treatment.

Cognitive behavioral therapy (CBT) often involves one-on-one meetings with a therapist, with the ultimate goal of solving the defective thinking process that's causing the disorder.

On average in the studies, people went through 12 sessions of therapy.

Compared to doing nothing, cognitive behavioral therapy had a "moderate" effect on helping people's anxiety.

Compared to medications or group discussions, the therapy relieved the disorder slightly better.

Gould's team noted that the improvement over other treatments was small.

"What this might mean clinically is that the client in the CBT condition might be a little less severely or moderately anxious relative to the client in the active control condition," Gould wrote in an email to Reuters Health.

GOING AFTER ROOT CAUSES

Gould says therapy might work better than drugs because it seeks to fix the causes of anxiety rather than the symptoms.

"If we can address the causes of symptoms of anxiety (e.g. by changing how we think about or interpret things) then we can stop them coming back in the future. If we only address the symptoms of anxiety then we can't," she said.

Though Gould's analysis and those of studies in younger adults agree that cognitive behavioral therapy helps treat anxiety, the effect in older adults is small while the effect seen in younger adults is moderate or large, the authors wrote.

Gould said she doesn't know why the therapy seems less effective in older adults, but it's possible that talk therapy might take longer to work for them.

Lenze said that cognitive behavioral therapy is still worthwhile in older adults.

"Until better treatments are developed there are somewhat limited options," he told Reuters Health.

He added that anxiety can take a toll on the mental and physical health of adults if it's not treated.

Gould said more studies that compare cognitive behavioral therapy to other treatments are needed in older adults, and her group is planning a study that explores the benefit of "mindfulness-based" cognitive therapy, which includes practices such as meditation.

Lenze said he and his colleagues are also exploring this approach, as well as combining cognitive behavioral therapy with medications.

SOURCE: http://bit.ly/xnZJJA Journal of the American Geriatrics Society, online January 27, 2012.


View the original article here

Malaria kills twice as many as thought - study

LONDON (Reuters) - Malaria kills more than 1.2 million people worldwide a year, nearly twice as many as previously thought, according to new research published on Friday that questions years of assumptions about the mosquito-borne disease.

Past studies had overlooked hundreds of thousands of deaths because they had wrongly assumed malaria overwhelmingly killed babies and focused their findings on under-fives, said the study by the Institute for Health Metrics and Evaluation (IHME) in the United States.

The new study, published in The Lancet medical journal, found 42 percent of deaths were actually among older children and adults.

The higher number of victims showed the need to increase funding to fight malaria, even as governments came under pressure to cut their aid budgets amid the global economic crisis, said the researchers.

"You learn in medical school that people exposed to malaria as children develop immunity and rarely die from malaria as adults," said Christopher Murray, who led the study as IHME Director. "What we've found in hospital records, death records, surveys and other sources shows that just is not the case."

In their work, which used new data and computer modelling to build a historical database for malaria between 1980 and 2010, they found that more than 78,000 children aged five to 14, and more than 445,000 people aged 15 and older died from malaria in 2010. This means more than four in 10 of all malaria deaths were in people aged five years and older.

Overall, malaria deaths worldwide rose from 995,000 in 1980 to a peak of 1.8 million in 2004, before falling again to 1.2 million in 2010, the study found.

The World Health Organisation's (WHO) latest global report said the estimated number of malaria deaths fell to 655,000 in 2010, almost half the number in the IHME study.

The WHO, a United Nations agency, said on Friday it stood by its figures and said that much of the data used in the Lancet study had been based on verbal testimony by relatives of how people had died, not on laboratory diagnosis of samples.

"So we would say that again the great majority of deaths would be in children under five and we stand by our estimates," WHO spokesman Gregory Hartl told a news briefing in Geneva.

Both studies showed a downward trend in deaths in recent years, thanks largely to the use of anti-malaria drugs and insecticide-treated bed nets.

The new findings are part of an ongoing series generated by the Global Burden of Diseases, Injuries and Risk Factors 2010 Study. Global trends in child deaths, maternal deaths, breast cancer, and cervical cancer were released last year [ID:nL5E7KF0NP] and more will be released in coming months.

Malaria is endemic in more than 100 countries worldwide but can be prevented by the use of bed nets and indoor spraying to keep the mosquitoes that carry the disease at bay.

Effective malaria drugs known as artemisinin-based combination therapies, or ACTs, can cure the infection but access to these medicines is often hampered in poor countries, where funding is limited and health services are patchy.

The IHME researchers said much of the decline in deaths was down to efforts by the Global Fund to Fight AIDS, Malaria and Tuberculosis, which was launched in 2001, and other anti-malaria organisations such as the WHO's Roll Back Malaria campaign.

"We have seen a huge increase in both funding and in policy attention given to malaria over the past decade, and it's having a real impact," said Alan Lopez of the University of Queensland and one of the study's co-authors.

"Reliably demonstrating just how big an impact is important to drive further investments... This makes it even more critical for us to generate accurate estimates for all deaths."

The researchers also warned, as the WHO did in its December 2010 malaria report, that recent gains in the fight against the disease malaria could be reversed if global economic troubles stifle funding efforts.

It said an announcement by the Global Fund in November that it would cancel its next round of funding "casts a cloud over the future of malaria programs.

"If the Global Fund is weakened, the world could lose 40 percent of all the funding dedicated to fighting malaria," said Stephen Lim, also at IHME and a co-author on the study.

(Additional reporting by Stephanie Nebehay in Geneva; Editing by Andrew Heavens)


View the original article here

Malaria toll far higher than thought: study

Malaria kills more than 1.2 million people a year, nearly 50 percent more than previously thought, and inflicts a high toll among adults and older children and not just toddlers, a new investigation says.

But there is also good news: deaths from the mosquito-borne disease have in fact been falling sharply thanks to access to better drugs and insecticide-treated nets.

Published in The Lancet on Friday, the study by the Institute of Health Metrics and Evaluation (IHME) at the University of Washington, Seattle, says malaria killed at least 1.2 million people worldwide in 2010.

The estimate will be a likely shock for health policymakers. Only last September the UN-backed Roll Back Malaria (RBM) calculated mortality in 2009 at 781,000.

The higher figure, say the US researchers, derives from wider and more reliable data, including use of a technique called "verbal autopsy".

Under this, investigators interview relatives of someone who has recently died in order to help pinpoint the cause of death. In many poor countries which lack medical infrastructure, mortality is often poorly probed or misidentified.

The new study skewers the belief that the overwhelming majority of malaria deaths occur among the under-fives.

In 2010, more than 78,000 children aged five to 14, and more than 445,000 aged 15 or older, died of malaria, together accounting for 42 percent of the total.

"You learn in medical school that people exposed to malaria as children develop immunity and rarely die from malaria as adults," said lead researcher Christopher Murray.

"What we have found in hospital records, death records, surveys and other sources shows that just is not the case."

From 1985, says the paper, malaria deaths grew every year, peaking at 1.8 million in 2004.

But from 2004, the toll fell every year. Between 2007 and 2010, the decline has been particularly acute -- more than seven percent every year -- and the big beneficiary has been Africa.

Among the stars are Tanzania and Zambia, which saw deaths fall by more than 30 percent between 2004 and 2010.

The source of the decline lies in the increased use of artemisinin drugs, replacing medications to which the malaria parasite has become resistant, and the widening distribution of insecticide-treated bed nets, says the probe.

The major players in this campaign are the Bill and Melinda Gates Foundation, RBM and the Global Fund to Fight AIDS, Malaria and Tuberculosis. Funding rose from less than 250 million dollars annually in 2001 to more than two billion in 2009.

"We have seen a huge increase in both funding and in policy attention given to malaria over the past decade, and it's having real impact," said Alan Lopez, a population health expert at the University of Queensland in Australia, who was a member of the research team.

The study warns of the dangers if the momentum is lost, especially in the shortfall of support for the Global Fund.

"There has been a rapid decrease in malaria mortality in Africa because of the scaling up of control activities supported by international donors," it says.

"Donor support, however, needs to be increased if malaria elimination and eradication and broader health and development goals are to be met."

In last September's estimate, RBM said mortality from malaria fell from 984,000 in 2000 to 781,000 in 2009, a decline of 38 percent if the world's population growth over this period is factored in.

The new study was funded by the Gates Foundation; however, the IHME is an independent research institution and The Lancet is a peer-reviewed journal.


View the original article here

Brains of addicts are inherently abnormal: study

Drug addicts have inherited abnormalities in some parts of the brain which interfere with impulse control, said a British study published in the United States on Thursday.

Previous research has pointed to these differences, but it was unclear if they resulted from the ravages of addiction or if they were there beforehand to predispose a person to drug abuse.

Scientists at the University of Cambridge compared the brains of addicts to their non-addicted siblings as well as to healthy, unrelated volunteers and found that the siblings shared many of the same weaknesses in their brains.

That indicates that the brain vulnerabilities had a family origin, though somehow the siblings of addicts -- either due to environmental factors or other differences in brain structure -- were able to resist addiction.

"Presumably, the siblings must have some other resilience factors that counteract the familial vulnerability to drug dependence," said the study led by Karen Ersche of the University of Cambridge, published in the journal Science.

"An individual's predisposition to become addicted to stimulant drugs may be mediated by brain abnormalities linked to impaired self-control."

Researchers tested 50 biological sibling pairs, in which one was addicted to drugs and the other one had no history of chronic drug abuse. They also tested 50 healthy, unrelated pairs of people as a control group.

The tests involved measuring how well they could control their impulses in a stop-signal reaction time test that assesses how quickly a person can switch from following one set of instructions to another.

Addicts are known to have poor impulse control.

The researchers found that the sibling pairs -- even the non-addicts -- fared significantly worse on the test than the healthy volunteers.

Brain scans showed that the siblings shared some of the same weaknesses in the frontal lobe and its connections to the basal ganglia, which mediates motor, cognition and behavior.

In an accompanying Perspective article, Nora Volkow and Ruben Baler of the US National Institute on Drug Abuse said that knowing more about brain circuitry could help understand and treat other "impaired control" disorders, like obesity, pathological gambling, attention deficit hyperactivity disorder, and obsessive-compulsive disorders.

"Several childhood and adolescent interventions can improve executive function and self-control," though more study is needed to see how such work may or may not impact the brain, they wrote.

ksh/ch


View the original article here

Green tea drinkers show less disability with age: study

NEW YORK (Reuters Health) - Elderly adults who regularly drink green tea may stay more agile and independent than their peers over time, a large study of Japanese adults suggests.

Green tea contains certain antioxidant chemicals -- particularly a compound known as EGCG -- that may help ward off the body-cell damage that can lead to disease. And researchers have been studying green tea's effects on everything from cholesterol to the risk of certain cancers -- with mixed results so far.

For the new study, Japanese researchers looked at a different question: Do green-tea drinkers have any lower risk of frailty and disability as they grow old?

Following nearly 14,000 adults age 65 and older, they found that people who drank the most green tea were the least likely to develop "functional disability" over the next three years.

Functional disability refers to problems with daily activities like going to the store or doing housework, or difficulty with more-basic needs like dressing and bathing.

In this study, almost 13 percent of adults who drank less than a cup of green tea per day became functionally disabled. That compared with just over 7 percent of people who drank at least five cups per day.

That alone does not prove that green tea keeps you spry into your golden years.

But the study, reported in the American Journal of Clinical Nutrition, did account for a range of factors that could explain the connection.

Green-tea lovers generally had healthier diets -- more fish, vegetables and fruit -- as well as more education, lower smoking rates, fewer heart attacks and strokes and greater mental sharpness.

They also tended to be more socially active and have more friends and family to rely on. (Studies have found that older adults with more "social support" are less likely to become disabled.)

But even with those factors considered, green tea itself was tied to a lower disability risk, according to the researchers, led by Yasutake Tomata of Tohoku University Graduate School of Medicine.

People who drank at least five cups a day were one-third less likely to develop disabilities than those who had less than a cup a day. And people who averaged three or four cups a day had a 25 percent lower risk.

All of that hints at a real effect of green tea. But ultimately, Tomata's team writes, definitive proof can come only from clinical trials testing the effects of green tea, or green tea extracts, on disability risk.

If green tea does offer a buffer against disability, it's not clear how.

But one recent study found that green tea extracts seemed to boost leg muscle strength in older women, notes Tomata's team, who could not be reached for comment.

In general, green tea is considered safe in moderate amounts. But the tea and its extracts do contain caffeine, which some people may need to avoid.

Green tea also contains small amounts of vitamin K, which means it could interfere with drugs that prevent blood-clotting, like warfarin. Since many elderly people are on multiple medications, it's wise for them to talk with their doctors before using green tea as a health tonic.

SOURCE: http://bit.ly/wXuZbl American Journal of Clinical Nutrition, online January 25, 2012.


View the original article here